141040-66-6

Basic information

• Product Name: 2,5-di-O-benzylmyoinositol
• Synonyms: 2,5-di-O-benzylmyoinositol
• CAS NO: 141040-66-6
• Molecular Formula: C₂₀H₂₄O₆
• Molecular Weight: 360.40096
• Mol File: 141040-66-6.mol

Chemical Properties

• Boiling Point: 532.9°Cat760mmHg
• Flash Point: 276.1°C
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 3.48E-12mmHg at 25°C
• Refractive Index: 1.635
• CAS DataBase Reference: 2,5-di-O-benzylmyoinositol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-di-O-benzylmyoinositol(141040-66-6)
• EPA Substance Registry System: 2,5-di-O-benzylmyoinositol(141040-66-6)

Safety Data

• Hazardous Substances Data: 141040-66-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,5-di-O-benzylmyoinositol is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its unique structure and properties make it a valuable component in the development of new drugs, particularly in the treatment of conditions such as diabetes and cancer.
Used in Agricultural Industry:
2,5-di-O-benzylmyoinositol is used as a component in the development of agricultural chemicals. Its potential applications in this field are currently being explored, with a focus on its possible contributions to crop protection and enhancement of agricultural productivity.
Used in Material Science:
2,5-di-O-benzylmyoinositol is used as a building block in the creation of new materials. Its chemical structure and properties lend themselves to the development of innovative materials with unique characteristics, which could have applications in various industries.
Used in Drug Delivery Systems:
2,5-di-O-benzylmyoinositol is used as a component in the design of drug delivery systems. Its potential to improve the delivery, bioavailability, and therapeutic outcomes of drugs is being researched, with a particular focus on its application in the treatment of diseases such as cancer.

InChI:InChI=1/C20H24O6/c21-15-17(23)20(26-12-14-9-5-2-6-10-14)18(24)16(22)19(15)25-11-13-7-3-1-4-8-13/h1-10,15-24H,11-12H2/t15-,16+,17-,18+,19?,20?

Upstream product

• 129662-36-8 (+/-)-1,4-Di-O-benzyl-2,3-di-O-(2-methoxyethoxymethyl)-chiro-inositol 
• 17793-95-2 (1RS,2RS)-cyclohexa-3,5-diene-1,2-diol 
• 129662-36-8 (1R,2S,3S,4R,5R,6S)-3,6-Bis-benzyloxy-4,5-bis-(2-methoxy-ethoxymethoxy)-cyclohexane-1,2-diol 
• 58706-20-0 (+/-)-3,6-di-O-benzyl-1,2:4,5-di-O-isopropylidene-myo-inositol 
• 111392-10-0 (+/-)-1,2:4,5-di-O-isopropylidene-3,6-di-O-p-methoxybenzyl-myo-inositol 
• 23486-92-2 3,6-di-O-benzyl-1,2:4,5-di-O-cyclohexylidene-D(L)-myo-inositol 
• 51548-88-0 (+/-)-1,2:4,5-di-O-isopropylidene-myo-inositol 
• 100-39-0 benzyl bromide 
• 824-94-2 p-methoxybenzyl chloride 
• 100-44-7 benzyl chloride 
• 130659-82-4 (5S,6S)-5,6-Bis-(2-methoxy-ethoxymethoxy)-cyclohex-2-ene-1,4-dione 
• 129662-35-7 C₂₈H₃₈O₈ 
• 130659-80-2 (4S,5R,6S)-4-Hydroxy-5,6-bis-(2-methoxy-ethoxymethoxy)-cyclohex-2-enone 
• 98906-25-3 (±)-1,2-O-isopropylidene-3,6-di-O-benzyl-myo-inositol 

Downstream Products

• 115432-20-7 octabenzyl (±)-2,3,5,6-(1,4-di-O-benzyl-myo-inosityl)tetrakisphosphate 
• 114218-20-1 (+/-)-3-O-allyl-1,4-di-O-benzyl-myo-inositol 
• 114218-20-1 (+/-)-2-O-allyl-1,4-di-O-benzyl-myo-inositol 
• 98906-25-3 (±)-1,2-O-isopropylidene-3,6-di-O-benzyl-myo-inositol 
• 98906-25-3 (+/-)-1,4-di-O-benzyl-5,6-O-isopropylidine-myo-inositol 
• 16749-94-3 (+/-)-2,3,4,5,6-penta-O-acetyl-1-O-benzyl-myo-inositol 
• 115184-71-9 (+/-)-1,3,4-tri-O-benzyl-myo-inositol 
• 131147-14-3 (+/-)-1,3,4,5-tetra-O-benzyl-myo-inositol 
• 142631-56-9 1,3,4,6-tetrakis-O-benzyl-myo-inositol 
• 111446-91-4 (+/-)-1,2,4-tri-O-benzyl-5,6-O-isopropylidene-myo-inositol 
• 98906-30-0 (±)-2,3,6-tri-O-benzyl-myo-inositol 
• 114218-16-5 1-O-allyl-2,3,6-tri-O-benzyl-myo-inositol 
• 114218-23-4 (+/-)-1-O-allyl-3,6-di-O-benzyl-4,5-O-isopropylidene-myo-inositol 
• 114218-19-8 1-O-Allyl-2,3,6-tri-O-benzyl-4,5-O-isopropylidene-myo-inositol 

Relevant articles and documents

Synthesis of oligo(spiroketal)s by polycondensation of silyl ethers derived from naturally occurring myo-inositol with 1,4-cyclohexanedione

Oligo(spiroketal)s (OSKs) were synthesized from myo-inositol, a naturally occurring cyclic compound bearing six hydroxyl groups. The successful synthesis of OSKs was achieved using silyl ethers 2 derived from 1,4-di-O-alkylated myo-inositol 1 as monomers,

Design and synthesis of lipid-coupled inositol 1,2,3,4,5,6-hexakisphosphate derivatives exhibiting high-affinity binding for the HIV-1 MA domain

The precursor of Gag protein (Pr55Gag) of human immunodeficiency virus, the principal structural component required for virus assembly, is known to bind d-myo-phosphatidylinositol 4,5-bisphosphate (PIP2). The N-terminus of Pr55G

Synthetic Inositol phosphate analogs reveal that PPIP5K2 has a surface-mounted substrate capture site that is a target for drug discovery

Diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) is one of the mammalian PPIP5K isoforms responsible for synthesis of diphosphoinositol polyphosphates (inositol pyrophosphates; PP-InsPs), regulatory molecules that function at the interface of cell s

On the kinetic resolution of sterically hindered myo-inositol derivatives in organic media by lipases

Sterically hindered myo-inositol derivatives were assayed against different commercial lipases. It was found that dl-1,3,6-tri-O-benzyl-myo-inositol undergoes efficient kinetic resolutions mediated by Pseudomonas sp. lipases (PS-C, PS-IM) and CaLB (Novozy

Tetrakisphosphates and Bispyrophosphates of myo-Inositol Derivatives as Allosteric Effectors of Human Hemoglobin: Synthesis, Molecular Recognition, and Oxygen Release

Various 2,5- and 1,4-substituted and unsubstituted myo-inositol tetrakisphosphates and bispyrophosphates were prepared following a general synthetic pathway. All final compounds were tested for their capability to induce oxygen release from human hemoglob

CYCLITOLS AND THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS

The present invention is directed to polyphosphorylated and pyrophosphate derivatives of cyclitols. More particularly, the invention relates to polyphosphorylated and pyrophosphate derivatives of inositols. The invention also relates to compositions of the polyphosphorylated and pyrophosphate derivatives of inositol and other similar, more lipophilic derivatives, and their use as allosteric effectors, cell-signaling molecule analogs, and therapeutic agents.

Synthesis of potent Ins(1,4,5)P3 5-phosphatase inhibitors by modification of myo-inositol 1,3,4,6-tetrakisphosphate

Three myo-inositol tetrakisphosphate analogues were synthesised based upon myo-inositol 1,3,4,6-tetrakisphosphate: 2,5-di-O-methyl myo-inositol-1,3,4,6-tetrakisphosphate 19 and its phosphorothioate derivative 22, together with myo-inositol 1,3,4,6 tetraki

The preparation and phosphorylation of 2,5- and 1D-2,6-di-O-benzyl-myo-inositol

1,3,4,6-Tetra-O-allyl-myo-inositol was converted into the 2,5-di-O-benzyl- and 2,5-di-O-p-methoxybenzyl ethers, and the products were deallylated to give the 2,5-di-O-benzyl (and p-methoxybenzyl) ethers of myo-inositol, which were converted into the mono-

Total synthesis of myo-inositol polyphosphates from benzene via conduritol B derivatives

The four (±)-myo-inositol phosphates 1,4,5-IP3 (1), 2,4,5-IP3 (15), 1,2,4,5-IP4 (17) and 4,5-IP2 (19) have been synthesised from benzene, using the protected conduritol B (10) as the key intermediate.

TOTAL SYNTHESIS OF chiro-INOSITOL 2,3,5-TRISPHOSPHATE: A myo-INOSITOL 1,4,5-TRISPHOSPHATE ANALOGUE FROM BENZENE VIA PHOTO-OXIDATION

The inositol tris- and tetrakis-phosphate analogues (4) and (14) have been synthesized from benzene by a sequence including reaction of singlet oxygen with a trans-cyclohexa-3,5-diene-1,2-diol (3) derivative.